33 Cipla, Lilly, GSK, Novartis Drugs Can Stay On India Market, DCGI Says
02:00 EDT 19 Jun 2012 | Elsevier Business Intelligence
A total of 33 drugs from Cipla, Eli Lilly, GlaxoSmithKline and Novartis were given a pass by Indian drug authorities and allowed to remain on the market even though no local clinical trials were conducted.
Original Article: 33 Cipla, Lilly, GSK, Novartis Drugs Can Stay On India Market, DCGI Says
More From BioPortfolio on "33 Cipla, Lilly, GSK, Novartis Drugs Can Stay On India Market, DCGI Says"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
